8-K

pf15040061-8k.txt

FORM 8K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

-----------

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2009

----------------

PFIZER INC.

-----------

(Exact name of registrant as specified in its charter)

Delaware 1-3619 13-5315170

-------- ------ ----------

(State or other (Commission File Number) (IRS Employer

jurisdiction of Identification

incorporation) Number)

235 East 42nd Street, New York, New York 10017

----------------------------------------------

(Address of principal executive offices) (zip code)

Registrant's telephone number, including area code: (212) 573-2323

--------------

Not Applicable

-----------------------------------------------

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to

simultaneously satisfy the filing obligation of the registrant under any of the

following provisions:

|X| Written communications pursuant to Rule 425 under the Securities Act (17 CFR

230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange

Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On January 26, 2009, Pfizer Inc. ("Pfizer"), issued a joint press release with

Wyeth ("Wyeth"), announcing the execution of an Agreement and Plan of Merger,

dated as of January 25, 2009, by and among Pfizer, Wagner Acquisition Corp., a

wholly-owned subsidiary of Pfizer and Wyeth. A copy of the joint press release

is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

On January 26, 2009, Pfizer also distributed a letter from Pfizer Chairman and

CEO, Jeffrey B. Kindler, to Pfizer's employees. A copy of the letter to

employees is attached hereto as Exhibit 99.2 and is incorporated by reference

herein. In addition, Pfizer provided supplemental information regarding the

proposed transaction in connection with a presentation to analysts. A copy of

the analyst presentation is attached hereto as Exhibit 99.3 and is incorporated

by reference herein.

Forward Looking Statements

--------------------------

This Current Report on Form 8-K (including information included or incorporated

by reference herein) includes "forward-looking statements" within the meaning of

the safe harbor provisions of the United States Private Securities Litigation

Reform Act of 1995. Such statements may include, but are not limited to,

statements about the benefits of the proposed merger between Pfizer and Wyeth,

including future financial and operating results, the combined company's plans,

objectives, expectations and intentions and other statements that are not

historical facts. Such statements are based upon the current beliefs and

expectations of Pfizer's and Wyeth's management and are subject to significant

risks and uncertainties. Actual results may differ from those set forth in the

forward-looking statements.

The following factors, among others, could cause actual results to differ from

those set forth in the forward-looking statements: the possibility that the

expected synergies from the proposed merger of Pfizer and Wyeth will not be

realized, or will not be realized within the expected time period, due to, among

other things, the impact of pharmaceutical industry regulation and pending

legislation that could affect the pharmaceutical industry; the ability to obtain

governmental and self-regulatory organization approvals of the merger on the

proposed terms and schedule; the failure of Wyeth stockholders to approve the

merger; the risk that the businesses will not be integrated successfully;

disruption from the merger making it more difficult to maintain business and

operational relationships; the possibility that the merger does not close,

including, but not limited to, due to the failure to satisfy the closing

conditions; Pfizer's and Wyeth's ability to accurately predict future market

conditions; dependence on the effectiveness of Pfizer's and Wyeth's patents and

other protections for innovative products; the risk of new and changing

regulation and health policies in the U.S. and internationally and the exposure

to litigation and/or regulatory actions. Additional factors that could cause

results to differ materially from those described in the forward-looking

statements can be found in Pfizer's 2007 Annual Report on Form 10-K, Wyeth's

2007 Annual Report on Form 10-K and each company's other filings with the

Securities and Exchange Commission (the "SEC") available at the SEC's Internet

site (http://www.sec.gov).

Additional Information

----------------------

In connection with the proposed merger, Pfizer will file with the SEC a

Registration Statement on Form S-4 that will include a proxy statement of Wyeth

that also constitutes a prospectus of Pfizer. Wyeth will mail the proxy

statement/prospectus to its stockholders. Pfizer and Wyeth urge investors and

security holders to read the proxy statement/prospectus regarding the proposed

merger when it becomes available because it will contain important information.

You may obtain copies of all documents filed with the SEC regarding this

transaction, free of charge, at the SEC's website (www.sec.gov). You may also

obtain these documents, free of charge, from Pfizer's website, www.pfizer.com,

under the tab "Investors" and then under the tab "SEC

Filings". You may also obtain these documents, free of charge, from Wyeth's

website, www.wyeth.com, under the heading "Investor Relations" and then under

the tab "Financial Reports/SEC Filings".

Pfizer, Wyeth and their respective directors, executive officers and certain

other members of management and employees may be soliciting proxies from Wyeth

stockholders in favor of the merger. Information regarding the persons who may,

under the rules of the SEC, be deemed participants in the solicitation of the

Wyeth stockholders in connection with the proposed merger will be set forth in

the proxy statement/prospectus when it is filed with the SEC. You can find

information about Pfizer's executive officers and directors in its definitive

proxy statement filed with the SEC on March 14, 2008. You can find information

about Wyeth's executive officers and directors in its definitive proxy statement

filed with the SEC on March 14, 2008. You can obtain free copies of these

documents from Pfizer and Wyeth using the contact information above.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

----------- -----------

99.1 Press Release, dated January 26, 2009.

99.2 Letter from Pfizer Chairman and CEO Jeffrey Kindler to Employees,

dated January 26, 2009.

99.3 Analyst Presentation.

SIGNATURES

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Mathew Lepore

----------------------------------------

Name: Mathew Lepore

Title: Vice President, Chief Counsel-

Corporate Governance, and Assistant

General Counsel

Dated: January 26, 2009

EXHIBIT INDEX

Paper (P) or

Exhibit No. Description Electronic (E)

------------- ---------------------------------------------- -------------------

99.1 Press Release, dated January 26, 2009. E

99.2 Letter from Pfizer Chairman and CEO Jeffrey E

Kindler to Employees, dated January 26, 2009.

99.3 Analyst Presentation. E